Log in with your email address username.


[Comment] Ureteric colic: evidence empowers responsible treatment

The urological community has for decades pursued studies of so-called off-label drugs—ie, pharmaceutical agents used for an unapproved or unintended indication—for treatment of urolithiasis. But perhaps urologists should question why the pharmaceutical industry has not expressed an interest in drug development for this indication. Most urologists might have never even thought about the consequences, secondary effects, or possible (serious) adverse events that can occur during off-label use of a drug.